Abdo Haddad1, Mellar Davis, Ruth Lagman. 1. Palliative Medicine Fellowship Faculty, The Harry R. Horvitz Center for Palliative Medicine, Cleveland Clinic Taussig Cancer Center, Cleveland, OH 44195, USA.
Abstract
BACKGROUND: Adverse drug interactions are major causes of morbidity, hospitalizations, and mortality. The greatest risk of drug interactions occurs through in the cytochrome system. CYP3A4, the most prevalent cytochrome, accounts for 30-50% of drugs metabolized through type I enzymes. MATERIALS AND METHODS: Palliative patients received medications for symptoms and co-morbidities, many of which are substrate, inhibitors, or promoters of CYP3A4 activity and expression. A literature review on CYP3A4 was performed pertinent to palliative medicine. DISCUSSION: In this state of the art review, we discuss the CYP3A4 genetics, and kinetics and common medications, which are substrates or inhibitor/promoters of CYP3A4. CONCLUSION: We made some recommendations for drug choices to avoid clinically important drug interaction.
BACKGROUND: Adverse drug interactions are major causes of morbidity, hospitalizations, and mortality. The greatest risk of drug interactions occurs through in the cytochrome system. CYP3A4, the most prevalent cytochrome, accounts for 30-50% of drugs metabolized through type I enzymes. MATERIALS AND METHODS: Palliative patients received medications for symptoms and co-morbidities, many of which are substrate, inhibitors, or promoters of CYP3A4 activity and expression. A literature review on CYP3A4 was performed pertinent to palliative medicine. DISCUSSION: In this state of the art review, we discuss the CYP3A4 genetics, and kinetics and common medications, which are substrates or inhibitor/promoters of CYP3A4. CONCLUSION: We made some recommendations for drug choices to avoid clinically important drug interaction.
Authors: M W Jann; L Ereshefsky; S R Saklad; D R Seidel; C M Davis; N R Burch; C L Bowden Journal: J Clin Psychopharmacol Date: 1985-04 Impact factor: 3.153
Authors: D R Nelson; L Koymans; T Kamataki; J J Stegeman; R Feyereisen; D J Waxman; M R Waterman; O Gotoh; M J Coon; R W Estabrook; I C Gunsalus; D W Nebert Journal: Pharmacogenetics Date: 1996-02
Authors: Shufeng Zhou; Sui Yung Chan; Boon Cher Goh; Eli Chan; Wei Duan; Min Huang; Howard L McLeod Journal: Clin Pharmacokinet Date: 2005 Impact factor: 5.577
Authors: M Apellániz-Ruiz; L Inglada-Pérez; M E G Naranjo; L Sánchez; V Mancikova; M Currás-Freixes; A A de Cubas; I Comino-Méndez; S Triki; A Rebai; M Rasool; G Moya; M Grazina; G Opocher; A Cascón; P Taboada-Echalar; M Ingelman-Sundberg; A Carracedo; M Robledo; A Llerena; C Rodríguez-Antona Journal: Pharmacogenomics J Date: 2014-11-04 Impact factor: 3.550